Search results
Arcturus Therapeutics (NASDAQ:ARCT) Shares Gap Down to $31.00
ETF DAILY NEWS· 4 days agoArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s share price gapped down prior to trading on Monday . The stock had previously closed at $31.00, but opened ...
Arcturus Therapeutics (NASDAQ:ARCT) Stock Price Down 4.4%
ETF DAILY NEWS· 5 days agoArcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Free Report)’s stock price was down 4.4% during mid-day trading on Friday . The company traded as low as $30.00 and ...
Cartesian Therapeutics (NASDAQ:RNAC) Given Buy Rating at HC Wainwright
ETF DAILY NEWS· 3 days agoHC Wainwright reiterated their buy rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $54.00 ...
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Digital Journal· 4 days agoOperations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its
Pfizer (NYSE:PFE) Trading 1.3% Higher
ETF DAILY NEWS· 20 hours agoPfizer Inc. (NYSE:PFE – Get Free Report) traded up 1.3% on Tuesday . The company traded as high as $27.38 and last traded at $27.32. 8,155,528 shares changed hands during trading, a decline ...
Worried you missed the Nvidia bandwagon? Here are some alternative stocks.
Market Watch· 6 days agoIs it too late for investors to jump on the Nvidia bandwagon? Maybe, but there are some alternative...
Cartesian Therapeutics (NASDAQ:RNAC) Receives “Outperform” Rating from Oppenheimer
ETF DAILY NEWS· 6 days agoOppenheimer restated their outperform rating on shares of Cartesian Therapeutics (NASDAQ:RNAC – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $50.00 price ...
Gateway - Quartz
Quartz· 2 days agoModerna said Tuesday that its updated COVID-19 vaccine demonstrated a stronger immune response than its current jab in results from a phase-3 clinical trial. The pharma Moderna stock ...
Analysts Set Pfizer Inc. (NYSE:PFE) Price Target at $35.86
ETF DAILY NEWS· 1 day agoPfizer Inc. (NYSE:PFE – Get Free Report) has been assigned an average rating of “Hold” from the fifteen ratings firms that are currently covering the stock, MarketBeat Ratings ...
Cantor Fitzgerald Reiterates “Overweight” Rating for Pfizer (NYSE:PFE)
ETF DAILY NEWS· 2 days agoPfizer (NYSE:PFE – Get Free Report)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report issued on Monday, Benzinga reports ...
